{
    "name": "mepolizumab",
    "comment": "Rx",
    "other_names": [
        "Nucala"
    ],
    "classes": [
        "Interleukin Inhibitors",
        "Monoclonal Antibodies",
        "Anti-asthmatics"
    ],
    "source": "https://reference.medscape.com/drug/nucala-mepolizumab-1000034",
    "pregnancy": {
        "common": [
            "Data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk",
            "Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters of pregnancy"
        ],
        "specific": [
            {
                "type": "Pregnancy exposure registry",
                "description": [
                    "Healthcare providers can enroll patients or encourage patients to enroll themselves by 1-877-311-8972 or www.mothertobaby.org/asthma"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate",
                    "Closely monitor the level of asthma control in pregnant women and treatment adjusted as necessary to maintain optimal control"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In a prenatal and postnatal development study, pregnant cynomolgus monkeys received mepolizumab from gestation days 20 to 140 at doses that produced exposures up to ~9 times that achieved with the MRHD (on an AUC basis with maternal IV doses up to 100 mg/kg once every 4 weeks)",
                    "Mepolizumab did not elicit adverse effects on fetal or neonatal growth (including immune function) up to 9 months after birth",
                    "Examinations for internal or skeletal malformations were not performed",
                    "Mepolizumab crossed the placenta in cynomolgus monkeys",
                    "Concentrations of mepolizumab were ~2.4 times higher in infants than in mothers up to day 178 postpartum"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "However, mepolizumab is a humanized monoclonal antibody (IgG1 kappa), and immunoglobulin G (IgG) is present in human milk in small amounts",
            "Present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy; levels in milk were ≤0.5% of maternal serum concentration",
            "Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (eg, angioedema, bronchospasm, hypotension, urticaria, rash) reported; these reactions generally occur within hours of administration, but in some instances can have a delayed onset (ie, days); discontinue drug in the event of a hypersensitivity reaction",
                "Not for treatment of acute asthma symptoms or acute exacerbations; do not use to treat acute bronchospasm or status asthmaticus; instruct patients to seek immediate medical advice if their asthma remains uncontrolled or worsens after initiating mepolizumab",
                "In clinical trials, 2 serious adverse reactions of herpes zoster occurred during treatment compared with none in placebo; consider varicella vaccination if medically appropriate before initiating treatment",
                "Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation mepolizumab; reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician; reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy",
                "Eosinophils may be involved in the immunological response to some helminth infections; patients with known parasitic infections were excluded from participation in clinical trials; treat patients with preexisting helminth infection before initiating mepolizumab; if helminth infection occurs while receiving mepolizumab that does not respond to treatment, discontinue mepolizumab until the infection resolves"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "19"
        },
        {
            "name": "Injection site reactions",
            "percent": "15"
        },
        {
            "name": "Injection site reactions",
            "percent": "8"
        },
        {
            "name": "Back pain",
            "percent": "5"
        },
        {
            "name": "Fatigue",
            "percent": "5"
        },
        {
            "name": "Influenza",
            "percent": "3"
        },
        {
            "name": "Urinary tract infection",
            "percent": "3"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "3"
        },
        {
            "name": "Pruritus",
            "percent": "3"
        },
        {
            "name": "Eczema",
            "percent": "3"
        },
        {
            "name": "Muscle spasms",
            "percent": "3"
        },
        {
            "name": "Abdominal pain",
            "percent": "3"
        },
        {
            "name": "Allergic rhinitis",
            "percent": "3"
        },
        {
            "name": "Asthenia",
            "percent": "3"
        },
        {
            "name": "Bronchitis",
            "percent": "3"
        },
        {
            "name": "Cystitis",
            "percent": "3"
        },
        {
            "name": "Dizziness",
            "percent": "3"
        },
        {
            "name": "Dyspnea",
            "percent": "3"
        },
        {
            "name": "Ear infection",
            "percent": "3"
        },
        {
            "name": "Gastroenteritis",
            "percent": "3"
        },
        {
            "name": "Lower respiratory tract infection",
            "percent": "3"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "3"
        },
        {
            "name": "Nasal congestion",
            "percent": "3"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "3"
        },
        {
            "name": "Toothache",
            "percent": "3"
        },
        {
            "name": "Viral infection",
            "percent": "3"
        },
        {
            "name": "Viral respiratory tract infection",
            "percent": "3"
        },
        {
            "name": "Systemic nonallergic reactions",
            "percent": "2"
        },
        {
            "name": "Systemic allergic",
            "percent": "1"
        },
        {
            "name": "hypersensitivity reactions",
            "percent": "8"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "6"
        },
        {
            "name": "Arthralgia",
            "percent": "3"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Nasal dryness",
            "percent": "3"
        },
        {
            "name": "Rash",
            "percent": "2"
        },
        {
            "name": "Injection site reactions",
            "percent": "4"
        },
        {
            "name": "Systemic allergic",
            "percent": "1"
        },
        {
            "name": "hypersensitivity reactions",
            "percent": "7"
        },
        {
            "name": "Systemic nonallergic reactions",
            "percent": "2"
        },
        {
            "name": "Injection site reaction",
            "percent": "1"
        },
        {
            "name": "Other systemic reactions",
            "percent": null
        },
        {
            "name": "ie",
            "percent": null
        },
        {
            "name": "multifocal skin reaction",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        }
    ]
}